On December 22, 2014, the U. S. Food and Drug Administration granted accelerated approval to nivolumab (OPDIVO, Bristol-Myers Squibb Company) for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if...
The U.S. Food and Drug Administration today approved a new use for Jakafi (ruxolitinib) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Jakafi is the first drug approved by the FDA for this condition.
On December 3, 2014, the U. S. Food and Drug Administration granted accelerated approval for blinatumomab (BLINCYTO, Amgen Inc.) for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (R/R ALL).
Dear Healthcare Provider, As you might know, the Genentech® Access to Care Foundation (GATCF) recently changed its eligibility criteria. The changes to the criteria were recently communicated to your practice via a letter from GATCF, but I wanted to ensure you...
